Amy Barton Pai, Pharm.D., BCPS, FASN, FCCP



Nephrology Fellowship, University of Illinois at Chicago 
Pharmacy Practice Residency, St. Peter’s Hospital
NIH-General Clinical Research Center Scholar’s Program, University of New Mexico
Pharm.D., Albany College of Pharmacy and Health Sciences 
B.S. Pharm, Albany College of Pharmacy and Health Sciences

Other Academic Appointments

Adjunct Associate Professor of Medicine, Albany Medical College, Albany, NY 
Associate Professor, University of New Mexico College of Pharmacy and School of Medicine (2001-2008)

Teaching Experience

Pharmacotherapy - Acute Kidney Injury, Clinical Pharmacokinetics
Integrated Problem Solving-Coordinator
Advanced Pharmacy Practice Experience

Research Interests

Dr. Barton Pai’s clinical and translational research program focuses on oxidative stress and inflammation in chronic kidney disease (CKD) patients. Her laboratory conducts in vivo and in vitro investigations of the effects intravenous iron compounds, vitamin D and other pharmaceuticals on cytokine activation, reactive oxygen species formation and lipid peroxidation to better understand the potential effects of the agents on cardiovascular disease in patients with kidney disease. Other research interests include pharmacokinetics and drug metabolism in CKD, effects of iron on gram-positive organism growth and infection and outcomes related to clinical pharmacy interventions in CKD patients. 

Dr. Barton Pai is also dedicated to training programs for aspiring clinical pharmacy scientists.

Honors and Achievements

Fellow, American Society of Nephrology
Fellow, American College of Clinical Pharmacy

Selected Publications

Kubotera N, Prokopienko A, Garba AO, Pai AB. Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status. Int J Nephrol. 2013;PMID 23401772

Pai AB, CardoneKE, ManleyHJ, St. PeterW,ShafferR, SomersM, MehrotraR.Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients: Need for a Systematic Approach. Clin  J Am Soc Nephrol. Invited Commentary. 2013 Nov;8(11):1988-99

 Manley HJ, Pai AB. Integrated Pharmacy Services: a necessary component for ESRD patient care. Am J Kidney Dis 2013;Sep;62(3):445-7

Conner TA, McQuade CR, Olp J, Pai AB. Effect of Intravenous Vitamin C  on Reactive Oxygen Species Generation, Cytokine Activation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous Iron Sucrose (IS). Biometals. 2012 Oct;25(5):961-9

Pai AB, Patel H, Prokopienko A, Gertzberg N, Alsaffar H, Neumann P, Punjabi A, Johnson A. Lipoteichoic acid from Staphylococcus aureus induces lung endothelial cell barrier dysfunction: role of reactive oxygen and nitrogen species. Plos One 2012;7(11) epub ahead of print

Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease: or another dark cloud? Journal of Blood Medicine 2012;3:77-85

Pai AB., Feleder C, Johnson A. Tumor Necrosis Factor-α (TNF) induces increased lung vascular permeability: a role for GSK3α/b. Eur J Pharmacol. 2011; epub ahead of print

Pai AB, McQuade C, Olp J. Hicks P, Conner T.  Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). Biometals 2011; Jan 13 

Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai AB. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrology 2010:11;16 

Pai AB, Nielson JC, Kausz A, Miller P, Owen J. Plasma Pharmacokinetics of two consecutive doses of ferumoxytol in Healthy Subjects. Clin Pharmacol Ther 2010;June 30:1-5 

Pai AB, Depczynski JC, Martinez I, Boyd A, Khan N, Manley HJ. Reduced Drug Use Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care-a 2 year randomized, controlled study.  Pharmacotherapy. 2009;29(12):1433-1440 

Demirovic J, Pai AB, Pai MP. Creatinine Clearance Estimation in Morbidly Obese Patients. Am J Health Syst Pharm 2009;66(7)642-648 

Boyd A, McQuade CR, Cooner TA, Manley HJ, Pai AB. Correlation between the Renal Quality of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Letter. Hemodial Int 2009;89-90 

Pai AB, Boyd A, Chavez A, Manley HJ. Health-related Quality of Life is Maintained in Hemodialysis Patients Receiving Pharmaceutical Care-A 2-Year Randomized, Controlled Study.  Hemodial Int; 2009;13:72-79 

Pai AB, Norenberg JP, Boyd A, Raj DSC, Chan L. Intravenous Iron is Associated with Increased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients. Clin Ther  2007;29:2699-2705 

Pai AB, Harford A, Boyd AV, McQuade C, Norenberg JP,  Zager P. Comparison of oxidative stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose. Pharmacotherapy 2007;27:343-350. 

Boyd AV, Townsend K, Dunne A, Spalding CT Pai AB. Optimal sampling for international normalized ratios in hemodialysis patients with central venous catheters. Nephrol Nurs J 2006;33:408 

Pai AB, Depczynski J, Pai MP, McQuade C, Mercier RC. Non‑transferrin bound iron is associated with enhanced staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 2006;26:304‑309

Department of Pharmacy Practice